One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists are antidiabetic drugs that possess a suppressive effect on the progression of atherosclerosis, and it has been thought that their anti-inflammatory effect is involved in their effect, but the detailed mechanism was unknown. Recently, Ben Nasr and colleagues have proposed easily understood mechanism for the anti-inflammatory effect of GLP-1 receptor agonists. They discovered that some normal T cells express GLP-1 receptors on their cell membranes and showed that GLP-1 has an inhibitory effect on T-cell function.

Authors

Institutions

Publication Details

Journal
Journal of Diabetes Investigation
Published
2024-11-13
DOI
https://doi.org/10.1111/jdi.14346
Citations
3
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
1.07

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists

Hirotaka Watada
3 citations
Journal of Diabetes Investigation
Diabetes Treatment and Management
1.07
article

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists

Hirotaka Watada
article en
3 citations

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are antidiabetic drugs that possess a suppressive effect on the progression of atherosclerosis, and it has been thought that their anti-inflammatory effect is involved in their effect, but the detailed mechanism was unknown. Recently, Ben Nasr and colleagues have proposed easily understood mechanism for the anti-inflammatory effect of GLP-1 receptor agonists. They discovered that some normal T cells express GLP-1 receptors on their cell membranes and showed that GLP-1 has an inhibitory effect on T-cell function.

Journal of Diabetes InvestigationVol. 16(2)
Juntendo University (JP)
Eli Lilly and Company, Abbott Japan, Kowa Company, Boehringer Ingelheim Japan, Novo Nordisk, MSD K.K., Eli Lilly Japan, Bayer Yakuhin, Novo Nordisk Pharma, Daiichi Sankyo Europe
Zero hunger
Openalex Percentile: Top 19%
Diabetes Treatment and Management
1.07
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.